Heart failure with reduced ejection fraction (aOR, 0.85; 95% CI, 0.79-0.91; P < .001) and HFpEF (aOR, 0.83; 95% CI, 0.77-0.89; P < .001) were independently associated with a lower rate of SGLT2 inhibitor use. Here, SLC5A2 is linked to heart failure.